Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.49 AUD | 0.00% | -10.91% | -14.04% |
05-28 | Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD | CI |
05-28 | Opthea Completes Enrollments in COAST, ShORe Trials | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.04% | 228M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- OPT Stock
- News Opthea Limited
- Opthea : Citigroup Initiates Coverage on Opthea With Buy Rating, $48 Price Target